The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality : Systematic Review and Meta-analysis
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case series. Studies published between January 1, 2020 to January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
| Errataetall: |
UpdateIn: Mayo Clin Proc. 2021 May;96(5):1262-1275. - PMID 33958057 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 02. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klassen, Stephen A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic UpdateIn: Mayo Clin Proc. 2021 May;96(5):1262-1275. - PMID 33958057 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.07.29.20162917 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317083643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317083643 | ||
| 003 | DE-627 | ||
| 005 | 20231225162503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.29.20162917 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM317083643 | ||
| 035 | |a (NLM)33140056 | ||
| 035 | |a (PII)2020.07.29.20162917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klassen, Stephen A |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality |b Systematic Review and Meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Mayo Clin Proc. 2021 May;96(5):1262-1275. - PMID 33958057 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case series. Studies published between January 1, 2020 to January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Senefeld, Jonathon |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Patrick W |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Rickey E |e verfasserin |4 aut | |
| 700 | 1 | |a Wiggins, Chad C |e verfasserin |4 aut | |
| 700 | 1 | |a Shoham, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Grossman, Brenda J |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Jeffrey P |e verfasserin |4 aut | |
| 700 | 1 | |a Musser, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Hartman, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvier, Nicole M |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Sean T H |e verfasserin |4 aut | |
| 700 | 1 | |a Pirofski, Liise-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Van Helmond, Noud |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, R Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Fairweather, DeLisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Katelyn A |e verfasserin |4 aut | |
| 700 | 1 | |a Paneth, Nigel S |e verfasserin |4 aut | |
| 700 | 1 | |a Casadevall, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Joyner, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 02. Feb. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.29.20162917 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 02 |c 02 | ||